Splash Beverage Group, Inc. has entered into an exclusive global licensing agreement with Argent BioPharma Limited for CannEpil®, a proprietary, patent-protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries. This acquisition allows Splash to leverage existing international commercialization while pursuing U.S. regulatory advancement. Drug-resistant epilepsy affects approximately 30% of epilepsy patients worldwide and remains one of the most significant unmet needs in neurology, with millions of patients continuing to experience uncontrolled seizures despite currently available therapies.

CannEpil is a pharmaceutical-grade cannabinoid-based treatment approved for distribution in multiple international markets, including Ireland, the United Kingdom, Germany, and Australia. The therapy is manufactured under European Union Good Manufacturing Practice (EU-GMP) standards and benefits from an existing international distribution infrastructure. "Acquiring exclusive global rights to CannEpil represents a transformational milestone for Splash," said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group.

Transaction Details

Under the terms of the agreement, Splash has acquired exclusive worldwide rights to develop, commercialize, market, distribute, sublicense, and sell CannEpil® for the treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders, and related neurological conditions. The license encompasses all global territories and includes rights to future product improvements, reformulations, and next-generation product developments within the licensed field. The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term and includes rights to sublicense the technology to strategic pharmaceutical partners globally.

Financial Considerations

As consideration for the transaction, Mercer Street Global Opportunity Fund agreed to forgive approximately $5 million of indebtedness owed by Argent BioPharma. Additionally, Splash agreed to issue $5.5 million of newly issued preferred equity. Argent BioPharma will receive a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.

Strategic Investment and Development

C/M Capital Partners has committed a $1 million strategic investment to support regulatory advancement, clinical development planning, commercialization initiatives, and strategic partnership activities. Splash intends to deploy these proceeds toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging leading U.S. epilepsy investigators, and identifying a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials.

Regulatory and Commercial Milestones

CannEpil has achieved significant commercial and regulatory milestones. In Ireland, the therapy is eligible under the Medicinal Cannabis Access Program (MCAP) and is supported through reimbursement mechanisms administered by the Health Service Executive (HSE). In the United Kingdom, CannEpil has been authorized for importation and prescription through the Named Patient Request framework and has been utilized through specialist treatment pathways. The program has also initiated formal engagement with the U.S. Food and Drug Administration through the pre-IND process and has been assigned an Investigational New Drug (IND) number.

Splash Beverage Group, Inc. (NYSE: SBEV) has completed a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products. The investment, finalized on June 9, 2026, involved the acquisition of 2,000,000 common shares and 1,000,000 warrants through a non-brokered private placement. This capital allocation aligns with Splash's previously announced transformation into a cannabinoid health, wellness, and healthcare-focused platform company.

The company views Avicanna as a sophisticated platform positioned for the evolution of the medical cannabinoid market in the United States. "Avicanna has spent years building many of the capabilities we believe will define the future of cannabinoid medicine," said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. He cited Avicanna's intellectual property, product portfolio, clinical development, and operational execution as key differentiators.

Strategic Attributes of Avicanna

Splash's investment thesis is supported by several attributes that distinguish Avicanna within the cannabinoid sector:

• One of North America's leading cannabinoid-based biopharmaceutical companies with proprietary formulations and clinical-stage pharmaceutical assets.
• A commercial-stage pharmaceutical portfolio that includes Trunerox™, an approved cannabidiol treatment for severe epilepsy indications.
• MyMedi.ca, a medical cannabis care platform providing pharmacist-led patient care and reimbursement support.
• Real-world operating experience within Canada's federally regulated medical cannabis system.
• A vertically integrated international platform with pharmaceutical-grade manufacturing in Colombia.
• An experienced management team with deep expertise across healthcare and pharmaceuticals.
• A debt-free balance sheet.

Investment Details

The following table outlines the specifics of the transaction:

Management believes the long-term cannabinoid opportunity will be defined by clinical evidence, physician participation, and regulatory compliance. Cobb noted that Avicanna operates within a federally regulated framework that incorporates characteristics increasingly evaluated in the U.S. healthcare system. Splash views this investment as a strategic allocation into a company suited for the next phase of cannabinoid medicine.